📗 Cite This Artifact
Davunetide (AL-108) PSP Trial
Trial Synopsis
Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. that was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies[@clinicaltrialsgov][@allon].
Overview
Trial Synopsis
Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. that was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies[@clinicaltrialsgov][@allon].
Overview
Davunetide (also known as AL-108, NAP, or NAPvasop) was a neuroprotective peptide developed by Allon Therapeutics Inc. It was evaluated in a Phase 2 clinical trial for Progressive Supranuclear Palsy (PSP). The trial failed to meet its primary endpoint, providing important lessons about neuroprotective strategies in tauopathies.[@clinicaltrialsgov][@allon]
Trial Details (Expanded)
| Parameter | Details |
|-----------|---------|
| Drug Name | Davunetide (AL-108, NAP) |
| Sponsor | Allon Therapeutics Inc. |
| ClinicalTrials.gov ID | NCT00490781 |
| Phase | Phase 2 |
| Status | Completed (Failed) |
| Duration | 12 months |
| Enrollment | Approximately 300 participants |
| Randomization | 1:1 davunetide:placebo |
| Blinding | Double-blind |
Key Trial Endpoints
| Endpoint Type | Measures |
|--------------|----------|
| Primary | Change in PSP Rating Scale (PSPRS) |
| Secondary | MMSE, ADAS-Cog, CGI-C |
| Exploratory | CSF biomarkers, MRI volumetrics |
Mechanism of Action
Davunetide was a synthetic peptide derived from the neuroprotective protein Activity-Dependent Neuroprotective Protein (ADNP). The drug was designed to:
The peptide was administered intranasally, which was designed to bypass the blood-brain barrier and deliver the drug directly to the brain.[@allon]
Rationale for PSP
PSP is characterized by tau pathology affecting the brainstem and subcortical structures. The neuroprotective mechanism of davunetide was considered relevant because:
- Tau dysfunction leads to microtubule destabilization
- Neuronal loss in PSP involves oxidative stress and excitotoxicity
- Neuroprotective approaches could potentially slow disease progression
Trial Results
The Phase 2 trial failed to demonstrate efficacy:
- Primary endpoint: No significant improvement in PSP Rating Scale (PSPRS) scores vs. placebo
- Secondary endpoints: No significant benefits in cognitive or motor measures
- Safety profile: Generally well-tolerated with mild-to-moderate adverse events
The negative result was considered a significant setback for neuroprotective approaches in PSP.[@clinicaltrialsgov]
Failure Analysis
Statistical Considerations
The trial's failure to meet its primary endpoint can be analyzed from multiple perspectives:
| Factor | Impact | Analysis |
|--------|--------|----------|
| Effect size | Small treatment effect | Insufficient power |
| Variability | PSPRS high variability | Sample size |
| Placebo | Natural progression | Disease trajectory |
| Dropouts | Missing data | ITT analysis |
Sensitivity Analyses
Post-hoc analyses may include:
Regulatory Considerations
The FDA Fast Track designation reflected the high unmet need in PSP:
- Unmet need: No approved disease-modifying therapies
- Serious condition: Progressive neurodegenerative disease
- Trial design: Traditional endpoint approach
- Outcome: Insufficient efficacy for approval
Impact on the Field
The davunetide failure had several impacts:
Potential Reasons for Failure
Lessons Learned
- Neuroprotective strategies may need to be initiated very early in disease course
- Combination approaches targeting multiple pathways may be more effective than single mechanisms
- Biomarker-driven patient selection could improve trial sensitivity
- Direct measurement of target engagement is critical for future trials
- Intranasal delivery may have limited CNS penetration for neuroprotective peptides
Clinical Development History
Timeline of Davunetide Development
| Year | Milestone | Status |
|------|----------|--------|
| 2005 | Preclinical neuroprotection demonstrated | Complete |
| 2006 | Phase 1 safety completed | Complete |
| 2007 | Phase 2a MCI/AD initiated | Complete |
| 2008 | Phase 2a results: Mixed signals | Complete |
| 2009 | PSP trial initiated | Complete |
| 2010 | Fast Track designation received | Complete |
| 2012 | PSP trial failed primary endpoint | Complete |
| 2013 | Program discontinued | Complete |
Competitive Landscape
The neuroprotective therapy field in tauopathies includes:
| Agent | Company | Mechanism | Status | Indication |
|-------|--------|-----------|--------|------------|
| Davunetide | Allon | Microtubule stabilization | Failed | PSP, AD |
| Taltirelin | Takeda | TRH analog | Phase 2 | PSP |
| Lithium | Various | GSK-3β inhibition | Phase 2 | PSP |
| Neflamapimod | EIP Pharma | p38 MAPK inhibition | Phase 2 | PSP |
| Masitinib | AB Science | Tyrosine kinase | Phase 3 | ALS |
Company Background
Allon Therapeutics was a biopharmaceutical company focused on developing neuroprotective therapies:
- Founded: 2001 (Vancouver, Canada)
- Focus: CNS neurodegenerative diseases
- Funding: ~$100M raised over company lifetime
- Employees: ~50 at peak
- Outcome: Ceased operations 2013 after trial failure
Intranasal Delivery Considerations
Rationale for Intranasal Administration
The intranasal route was chosen for several reasons[@insua2007]:
| Factor | Consideration |
|--------|---------------|
| BBB penetration | Direct nose-to-brain delivery |
| Reduced systemic exposure | Lower side effects |
| Non-invasive | Patient acceptance |
| Rapid onset | Quick brain entry |
Challenges with Intranasal Delivery
Despite the rationale, challenges included:
Alternative Delivery Methods Considered
Other delivery approaches that could be explored:
| Route | Advantages | Disadvantages |
|-------|-------------|---------------|
| Intravenous | Precise dosing | BBB penetration |
| Intraventricular | Direct CNS | Invasive |
| Intrathecal | Spinal cord target | Surgical |
| Intranasal | Non-invasive | Variable |
| Oral | Patient-friendly | Poor CNS penetration |
Therapeutic Implications
Why Neuroprotection Fails in Established Disease
The davunetide trial failure reflects broader challenges:
| Factor | Explanation |
|--------|-------------|
| Advanced pathology | Established neurodegeneration may be irreversible |
| Multiple mechanisms | Single-target approaches may be insufficient |
| Biomarker gaps | Cannot confirm target engagement |
| Timing | Too late in disease course |
Future Directions for Neuroprotection
Based on lessons learned:
Ongoing Neuroprotective Strategies
Similar neuroprotective strategies still being explored in PSP include:
- [Microtubule stabilizers - Other compounds targeting microtubule function](/therapeutics/microtubule-stabilizers)
- [Anti-tau antibodies - Immunotherapy approaches (e.g., gosuranemab, tilavonemab, semorinemab)](/therapeutics/tau-immunotherapy)
- [Tau ASOs - Antisense oligonucleotides targeting tau (e.g., BIIB080/MAPTRx, NIO752, IONIS-MAPTRx)(see NCT05348786)](/therapeutics/antisense-oligonucleotide-therapy-neurodegeneration)
- [Tau aggregation inhibitors - Drugs preventing tau misfolding](/therapeutics/tau-aggregation-inhibitors)
- [Neurotrophic factors - BDNF mimetics and NGF modulators](/therapeutics/neurotrophic-factor-therapies)
Regulatory History
Development Timeline
| Year | Event |
|------|-------|
| 2005 | Preclinical studies demonstrate neuroprotective activity |
| 2007 | Phase 1 trial initiated |
| 2009 | Phase 2 trial in PSP initiated |
| 2012 | Trial failed to meet primary endpoint |
| 2013 | Allon Therapeutics ceased operations |
| 2014-2025 | Program not pursued further |
FDA Interaction
The FDA granted Fast Track designation to davunetide for PSP in 2010, acknowledging the high unmet need in this indication. Despite this designation, the negative Phase 2 results led to program discontinuation.
Mechanism Deep Dive
ADNP and Navops
Davunetide is derived from ADNP (Activity-Dependent Neuroprotective Protein), a naturally occurring neuroprotective protein:
- ADNP function: Regulates neuronal survival, plasticity, and function
- ADNP activity: Protects against various neurotoxic insults
- Davunetide (NAP): 8-amino acid peptide representing the active domain
Molecular Targets
- Binds to microtubule-associated proteins (MAPs)
- Prevents tau-induced microtubule dysfunction
- Maintains axonal transport
- Modulates Bcl-2 family proteins
- Reduces caspase activation
- Preserves mitochondrial integrity
- Reduces pro-inflammatory cytokine release
- Modulates microglia activation
- May reduce neuroinflammation in tauopathies
Target Engagement and Biomarkers
Challenges in Demonstrating Target Engagement
The davunetide trial highlights a critical challenge in neuroprotective drug development—the inability to directly measure target engagement in the brain:
| Challenge | Impact | Mitigation |
|-----------|--------|----------|
| BBB penetration unknown | Cannot confirm brain exposure | CSF sampling, PET ligands |
| Microtubule binding | Cannot measure in vivo | Surrogate biomarkers |
| Functional endpoint | Clinical readouts delayed | Longer trials |
| Mechanism validation | Cannot confirm MOA | Post-mortem studies |
Biomarker Approaches for Future Trials
Future neuroprotective trials could incorporate:
| Biomarker Type | Purpose | Example |
|-----------------|---------|----------|
| CSF biomarkers | Target engagement | Tau, p-tau, NFL |
| Neuroimaging | Structural changes | MRI volumetrics |
| PET ligands | Protein burden | Tau PET |
| Genetic | Patient stratification | Risk variants |
Monitoring Neuronal Health
In the absence of direct target engagement measures, alternative approaches include:
Summary and Legacy
Trial Outcome Summary
The davunetide PSP Phase 2 trial represents an illustrative case study in CNS drug development:
| Parameter | Expected | Actual |
|-----------|----------|--------|
| Primary endpoint | PSPRS improvement | No difference |
| Secondary endpoints | Cognitive benefit | No benefit |
| Safety | Acceptable profile | Well-tolerated |
| Efficacy | Disease modification | Failed |
The negative result was unexpected given positive preclinical data, highlighting the challenge of translating animal model findings to human neurodegenerative disease.
Contributing Factors to Failure
Multiple factors contributed to the trial failure:
Lasting Legacy
Despite the negative outcome, the program contributed lasting value:
Industry Context
The trial occurred during a period of intense investment in neuroprotective therapies:
- 2000s: Peak of neuroprotective drug development
- Funding environment: Significant venture capital interest
- Company landscape: Multiple biotech focused on neuroprotection
- Outcome: Many failures led to field consolidation
Future Therapy Directions
Current approaches building on lessons learned:
| Approach | Learning Applied | Status |
|-----------|-------------------|--------|
| Tau ASOs | Target specific production | Phase 1/2 |
| Gene therapy | Continuous protein expression | Preclinical |
| Combination | Multi-target approaches | Phase 2 |
| Biomarker-driven | Patient selection | Emerging |
Comparison with Other Approaches
Neuroprotective Mechanisms in Clinical Development
| Agent | Target | Route | Stage | Indication |
|-------|--------|-------|-------|------------|
| Davunetide | Microtubule | Intranasal | Phase 2 | Failed |
| Taltirelin | TRH analog | Oral | Phase 2 | PSP |
| Lithium | GSK-3β | Oral | Phase 2 | PSP |
| Neflamapimod | p38 MAPK | Oral | Phase 2 | PSP |
| AZP2006 | ApoE | Oral | Phase 1 | PSP |
Preclinical Data Summary
Animal Model Evidence
The preclinical program included multiple animal model studies:
| Study | Model | Findings |
|-------|-------|----------|
| Stroke models | MCAO rats | Reduced infarct size |
| PD models | 6-OHDA rats | Neuroprotection |
| AD models | 3xTg mice | Improved cognition |
| Aging | Aged rodents | Cognitive improvement |
Translation Challenges
The translation from animal models to human trials faced challenges:
| Factor | Animal Models | Human Trials | Gap |
|--------|--------------|-------------|-----|
| Disease stage | Acute injury | Chronic disease | Significant |
| Pathology | Induced | Progressive | Significant |
| Delivery | Injection | Intranasal | Moderate |
| Outcome | Survival | Function | Moderate |
Species Differences
Key differences between preclinical species and humans:
Biomarker Correlations
The trial incorporated exploratory biomarker analyses:
| Biomarker | Sampling | Findings |
|-----------|----------|----------|
| Total tau | CSF | Elevated in PSP |
| Phosphorylated tau | CSF | Increased with progression |
| Neurofilament light | CSF | Correlated with atrophy |
| Amyloid-beta 40/42 | CSF | Not a primary factor |
Imaging Correlations
Neuroimaging was integrated to understand treatment effects:
| Modality | Purpose | Finding |
|----------|---------|----------|
| MRI brainstem | Regional volumetrics | Progression in disease regions |
| MR spectroscopy | Metabolite levels | Limited sensitivity |
| DAT imaging | Dopaminergic integrity | Not treatment-related |
The imaging findings confirmed disease progression despite treatment, suggesting inadequate biological activity of davunetide at the achieved brain concentrations.
Impact on Neuroprotective Drug Development
Industry Implications
The davunetide failure affected the broader neuroprotective drug development landscape:
| Impact | Area | Effect |
|--------|------|-------|
| Funding | Venture capital | Decreased |
| Pipeline | Company pipelines | Reduced |
| Partnerships | Pharma interest | Diminished |
| Trials | Clinical programs | Consolidation |
Academic Research Implications
The failure also influenced academic research directions:
Future Outlook
Lessons for Future Trials
Alternative Delivery Methods
Future neuroprotective approaches may explore:
- Intravenous delivery with BBB-penetrating peptides
- Intraventricular infusion for direct CNS delivery
- Gene therapy for continuous neuroprotective protein expression
- Exosome-mediated delivery for targeted CNS delivery
Clinical and Regulatory Insights
Trial Design Implications
The Phase 2 trial design reflected the challenges inherent in neuroprotective drug development for chronic neurodegenerative diseases:
| Design Element | Rationale | Limitation |
|---------------|-----------|-----------|
| 12-month duration | Sufficient for progression | May be too short |
| PSPRS primary | Standard PSP measure | Insensitive to change |
| 1:1 randomization | Balanced groups | Standard |
| Double-blind | Reduce bias | Cannot confirm compliance |
Statistical Power
The trial was designed to detect a clinically meaningful difference:
- Assumed effect size: 3-4 points on PSPRS
- Variability assumptions: Based on natural history
- Power: 80% to detect difference at p<0.05
- Result: Not achieved - insufficient power or no effect
Post-Trial Analyses
Comprehensive analyses after trial completion:
Economic Considerations
The trial represented significant investment:
| Cost Category | Estimate |
|--------------|----------|
| Preclinical | $20-30M |
| Clinical operations | $40-60M |
| Manufacturing | $10-15M |
| Regulatory | $5-10M |
| Total | $75-115M |
Cross-Links to NeuroWiki
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Conclusion and Final Assessment
Clinical Significance
The davunetide Phase 2 trial in PSP, while ultimately unsuccessful, represents an important chapter in neurodegeneration drug development:
| Dimension | Assessment |
|-----------|-----------|
| Scientific contribution | Advanced understanding of microtubule biology |
| Clinical infrastructure | Established PSP trial network |
| Lessons learned | Critical insights for future trials |
| Field impact | Influenced neuroprotective strategies |
Path Forward
The failure of davunetide and similar neuroprotective approaches points toward a new paradigm:
The neuroscience community continues to build on these lessons, with ongoing programs applying the insights gained from this and similar trials.
Final Takeaways and Summary
The Phase 2 clinical trial of davunetide (AL-108) in PSP represents an important case study in neuroprotective drug development for tauopathies. The trial failure provides critical lessons for the field:
Key Learnings:
- Single-target neuroprotection is insufficient for established PSP
- Intranasal delivery may not achieve adequate CNS concentrations
- Disease modification requires very early intervention
- Biomarkers are essential for target engagement confirmation
- Focus on prodromal/preventive interventions
- Develop biomarker-driven patient stratification
- Pursue multi-target combination approaches
- Improve CNS delivery methods
The legacy of the davunetide program continues to inform neuroprotective drug development for PSP and related tauopathies.
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
- [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
- [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
- [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
- [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
- [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
- [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1
Related Analyses:
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Davunetide (AL-108) PSP Trial discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-davunetide-al108-psp |
| kg_node_id | None |
| entity_type | clinical |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-53fbc442d549 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-davunetide-al108-psp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-davunetide-al108-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Davunetide (AL-108) PSP Trial](http://scidex.ai/artifact/wiki-clinical-trials-davunetide-al108-psp)
http://scidex.ai/artifact/wiki-clinical-trials-davunetide-al108-psp